Patterns of methylphenidate use and assessment of its abuse and diversion in two french administrative areas using a proxy of deviant behaviour determined from a reimbursement database: Main trends from 2005 to 2008

CNS Drugs

Volumn 25, Issue 5, 2011, Pages 415-424

  Frauger, Elisabeth ^a,b   Pauly, Vanessa ^c   Natali, François ^d   Pradel, Vincent ^a,c   Reggio, Patrick ^d   Coudert, Herv ^d   Thirion, Xavier ^c   Micallef, Joëlle ^a  

^a Centre d'Evaluation et d'Information sur la Pharmacodépendance Addictovigilance   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c AIX MARSEILLE UNIVERSITY   (France)

^d Direction Regionale du Service Medical de la Region Provence Alpes Cote d'Azur et Corse   (France)

Author keywords

Attention deficit and disruptive behaviour disorders; Drug abuse; Methylphenidate, therapeutic use

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE; BUPRENORPHINE; FLUNITRAZEPAM; METHADONE; METHYLPHENIDATE; NARCOTIC ANALGESIC AGENT; NEUROLEPTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; DRUG ABUSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; FEMALE; FRANCE; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL; REIMBURSEMENT;

EID: 79953896008     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11587640-000000000-00000     Document Type: Article

References (49)

1. McCabe SE, Teter CJ, Boyd CJ, et al. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. J Adolesc Health 2004 Dec; 35 (6): 501-4 (Pubitemid 39576021)
2. Stoops WW, Glaser PE, Rush CR. Reinforcing, subject-rated, and physiological effects of intranasal methylpheni-date in humans: a dose-response analysis. Drug Alcohol Depend 2003 Aug 20; 71 (2): 179-86 (Pubitemid 37289027)
3. Wigal S. Efficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adults. CNS Drugs 2009; 23 Suppl. 1: 21-31
4. Berbatis CG, Sunderland VB, Bulsara M. Licit psychostim-ulant consumption in Australia, 1984-2000: international and jurisdictional comparison. Med J Aust 2002 Nov 18; 177 (10): 539-43 (Pubitemid 35422816)
5. Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009 May; 2 (2): 157-76
6. Kollins SH, MacDonald EK, Rush CR. Assessing the abuse potential of methylphenidate in nonhuman and human subjects: a review. Pharmacol Biochem Behav 2001 Mar; 68 (3): 611-27
7. Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008 Jan; 47 (1): 21-31
8. Kollins SH. ADHD, substance use disorders, and psychostimulant treatment: current literature and treatment guidelines. J Atten Disord 2008 Sep; 12 (2): 115-25
9. Parasrampuria DA, Schoedel KA, Schuller R, et al. Do formulation differences alter abuse liability of methyl-phenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007 Oct; 27 (5): 459-67 (Pubitemid 47415043)
10. DAWN. National estimates, drug-related emergency department visits for 2004-2008 [online]. Available from URL http://dawninfo.samhsa.gov/data/ed/ National/Na tional-2008-NMUP.xls [Accessed 2010 Mar 26]
11. Bright GM. Abuse of medications employed for the treat-ment of ADHD: results from a large-scale community survey. Medscape J Med 2008 May 7; 10 (5): 111
12. Farquhar S, Fawcett P, Fountain J. Illicit intravenous use of methylphenidate (Ritalin) tablets: a review of four cases. Aust Emerg Nurs J 2002 Aug; 5 (2): 25-9
13. DeSantis AD, Webb EM, Noar SM. Illicit use of prescrip-tion ADHD medications on a college campus: a multi-methodological approach. J Am Coll Health 2008 Nov-Dec; 57 (3): 315-24
14. Teter CJ, McCabe SE, LaGrange K, et al. Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration. Pharmacotherapy 2006 Oct; 26 (10): 1501-10 (Pubitemid 44521735)
15. Poulin C. From attention-deficit/hyperactivity disorder to medical stimulant use to the diversion of prescribed stimulants to non-medical stimulant use: connecting the dots. Addiction 2007 May; 102 (5): 740-51 (Pubitemid 46633355)
16. U.S. Department of Health and Human Services. National Survey on Drug Use and Health (NSDUH) [online]. Available from URL http://www.oas.samhsa.gov/ NSDUH. HTM [Accessed 2010 Mar 26]
17. O'Brien MS, Anthony JC. Extra-medical stimulant dependence among recent initiates. Drug Alcohol Depend 2009 Sep 1; 104 (1-2): 147-55
18. Bramness JG, Furu K, Engeland A, et al. Carisoprodol use and abuse in Norway: a pharmacoepidemiological study. Br J Clin Pharmacol 2007; 4 (2): 210-8 (Pubitemid 47063238)
19. Katz N, Panas L, Kim ML, et al. Usefulness of prescription monitoring programs for surveillance: analysis of Schedule II opioid prescription data in Massachusetts, 1996-2006. Pharmacoepidemiol Drug Saf 2009 Dec; 19 (2): 115-26
20. Wilsey BL, Fishman SM, Gilson AM, et al. Profiling multiple provider prescribing of opioids, benzodiazepines, stimulants, and anorectics. Drug Alcohol Depend 2010 Nov 1; 112 (1-2): 99-106
21. Martin-Latry K, Begaud B. Pharmacoepidemiological re-search using French reimbursement databases: yes we can! Pharmacoepidemiol Drug Saf 2010 Mar; 19 (3): 256-65
22. Micallef J, Pradel V, Thirion X, et al. Use of the health insurance database by the centres for evaluation and information on pharmacodependance: examples, interests and future prospects [in French]. Therapie 2004; 59: 581-8 (Pubitemid 40353959)
23. Knellwolf AL, Deligne J, Chiarotti F, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008 Mar; 64 (3): 311-7
24. Frances C, Hoizey G, Millart H, et al. Paediatric methyl-phenidate (Ritalin) restrictive conditions of prescription in France. Br J Clin Pharmacol 2004 Jan; 57 (1): 115-6 (Pubitemid 38067958)
25. Ministere de la solidarite, de la sante et de la protection so-ciale. Arrete du 22 fevrier 1990 fixant la liste des substances classees comme stupefiants [online]. Available from URL. http://www.legifrance.gouv.fr/ affichTexte.do?cidTexte=JORF TEXT000000533085&dateTexte= [Accessed 2011 Feb 21]
26. Strom BL. Pharmacoepidemiology. 3rd ed. West Sussex: John Wiley & Sons, Ltd, 2000
27. WHO Collaborating Centre for Drug Statistics Methodol-ogy. Guidelines for ATC classification and DDD assignment [online]. Available from URL http://www.whocc.no/ atcddd / [Accessed 2009 Jan 29]
28. Frauger E, Thirion X, Chanut C, et al. Misuse of trihexy-phenidyl (Artane, Parkinane): recent trends [in French]. Therapie 2003; 58: 541-7 (Pubitemid 38327276)
29. Frauger E, Pradel V, Natali F, et al. Misuse of clonazepam (Rivotril): recent trends [in French]. Therapie 2006; 61: 49-55 (Pubitemid 350213994)
30. Frauger E, Pauly V, Thirion X, et al. Estimation of clona-zepam abuse liability: a new method using a reimbursed drug database. Int Clin Psychopharmacol 2009 Nov; 24 (6): 318-24
31. Trip AM, Visser ST, Kalverdijk LJ, et al. Large increase of the use of psychostimulants among youth in the Netherlands between 1996 and 2006. Br J Clin Pharmacol 2009 Apr; 67 (4): 466-8
32. Portenoy RK, Itri LM. Cancer-related fatigue: guidelines for evaluation and management. Oncologist 1999; 4 (1): 1-10 (Pubitemid 29102450)
33. Laval G, Paris A. Methylphenidate in palliative care in can-cer patient: a double-blind randomised trial versus placebo. Bull Cancer 2008 Feb; 95 (2): 241-6 (Pubitemid 351341294)
34. Padala PR, Burke WJ, Shostrom VK, et al. Methylpheni-date for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry 2010 Apr; 18 (4): 371-4
35. Miller AR, Lalonde CE, McGrail KM, et al. Prescription of methylphenidate to children and youth, 1990-1996. CMAJ 2001 Nov 27; 165 (11): 1489-94 (Pubitemid 34060191)
36. Volkow ND. Stimulant medications: how to minimize their reinforcing effects? Am J Psychiatry 2006 Mar; 163 (3): 359-61 (Pubitemid 44469374)
37. Leonard BE, McCartan D, White J, et al. Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects. Hum Psychopharmacol 2004 Apr; 19 (3): 151-80 (Pubitemid 38514828)
38. Tiihonen J, Kuoppasalmi K, Fohr J, et al. A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiatry 2007 Jan; 164 (1): 160-2 (Pubitemid 46154797)
39. Sahakian B, Morein-Zamir S. Professor's little helper. Nature 2007; 450: 1157-9
40. Pradel V, Frauger E, Thirion X, et al. Comparison of abuse potential of psychotropic medication in real life setting [abstract]. Fundam Clin Pharmacol 2007; 1: 50
41. Ministere de la sante, de la jeunesse, des sports et de la vie associative. Arrete du 1er avril 2008 relatif a la liste de soins ou traitements susceptibles de faire l'objet de mesusage, d'un usage detourne ou abusif, pris en application de l'ar-ticle L. 162-4-2 du code de la securite sociale [online]. Available from URL http://www.legifrance.gouv.fr/af fichTexte.do;jsessionid= D4E6857854925CD0754A976F18 F8030B.tpdjo17v-1?cidTexte=JORFTEXT000018598614 &dateTexte=&oldAction=rechJO&categorieLien=id [Accessed 2010 Mar 26]
42. Pradel V, Frauger E, Thirion X, et al. Impact of a prescrip-tion monitoring program on doctor-shopping for high dosage buprenorphine. Pharmacoepidemiol Drug Saf 2009; 18: 36-43
43. Modelon H, Frauger E, Laurenceau D, et al. Psychotropic drug addiction: consumption study of specific population by the survey OPPIDUM 2004 from the CEIP network [in French]. Therapie 2007; 62: 337-46 (Pubitemid 351211749)
44. Boeuf O, Lapeyre-Mestre M, French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse in France: results of OSIAP survey. Drug Saf 2007; 30: 265-76 (Pubitemid 46425637)
45. Pradel V, Delga C, Rouby F, et al. Assessment of abuse potential of benzodiazepines in prescription database with doctor shopping indicator. CNS Drugs 2010 Jul 1; 24 (7): 611-20
46. Victorri-Vigneau C, Basset G, Bourin M, et al. Impacts of the new flunitrazepam regulations on the consumption of hypnotics [in French]. Therapie 2003 Sep-Oct; 58 (5): 425-30
47. Greely H, Sahakian B, Harris J, et al. Towards responsible use of cognitive-enhancing drugs by the healthy. Nature 2008 Dec 11; 456 (7223): 702-5
48. Chatterjee A. Is it acceptable for people to take methyl-phenidate to enhance performance? No [letter]. BMJ 2009 Jun 18; 338: b1956
49. Harris J. Is it acceptable for people to take methylphenidate to enhance performance? Yes [letter]. BMJ 2009 Jun 18; 338: b1955